A compound of the general formula wherein: Y represents -CH 2 - or >C=O; R 1 is selected from the group consisting of A1, A2 and A3: R 2 represents: - dioxothiomorpholino moiety B1; - piperazinyl moiety B2 wherein two carbon atoms of the piperazine ring can be optionally joined with methylene bridge -CH 2 - to form 2,5-diazabicyclic moiety, and R 5 is selected from the group consisting of -SO 2 CH 3; -C -C1-C3-alkyl, -C -C3-C5-cycloalkyl; phenyl substituted with -O-C1-C3 alkyl; and -CR 6 R 7 R 8, wherein R 6, R 7 and R 8 independently represent hydrogen atom, CH 3, cyclopropyl or CONH 2, with the proviso that only one of R 6, R 7 and R 8 can represent cyclopropyl or CONH 2, or one of R 6, R 7 and R 8 represents hydrogen atom and remaining two of R 6, R 7 and R 8 are joined together to form -(CH 2) 2, -(CH 2) 3, -(CH 2) 4, or -(CH 2 -O-CH 2)- group; - azetidinyl moiety B3 wherein R 9 is selected from the group consisting of morpholino, 2,6-dimethylomorpholino, 1,1-dioxothiomorpholino, 4,4-difluoropiperidynyl and 3-methoxyazetidin-1-yl; or - piperidinyl moiety B4 wherein R 10 is selected from the group consisting of C1-C4 alkyl; C1-C4 alkyl substituted with OH; -COO(C1-C3 alkyl); -N(C1-C3 alkyl) 2; -NHCONH-C1-C3-alkyl; -NHCONH-C1-C3-phenyl; piperazinyl; and piperazinyl substituted at the position 4 with C1-C3 alkyl; R 3 is selected from the group consisting of H, halogen, and C1-C4 alkyl; R 4 is selected from the group consisting of C1-C4 alkyl, C3-C4-cycloalkyl, C1-C4 alkyl substituted with C1-C4 alkoxy, and CHF 2; X 1 and X 2 have the following meanings: (i) X 1 represents CH and X 2 represents CH or N; (ii) X 1 represents N and X 2 represents CH, or (iii) X 1 represents CH and X 2 represents C-O-CH 3; X 3, X 4, X 5 and X 6 have the following meanings: (i) X 3 represents N, X 4 represents CH, X 5 represents CH, and X 6 represents CH; (ii) X 3 represents CH, X 4 represents N, X 5 represents CH, and X 6 represents CH; (iii) X 3 represents CH, X 4 represents CH, X 5 represents N, and X 6 represents CH; (iv) X 3 represents CH, X 4 represents CH, X 5 represents CH, and X 6 represents CH or CF; or (v) X 3 represents CH, X 4 represents CH, X 5 represents CF, and X 6 represents CH; X 7 represents CH or N; wavy line indicates the point of attachment; and pharmaceutically acceptable salts thereof. Y represents -CH 2 - or >C=O; R 1 is selected from the group consisting of A1, A2 and A3: R 2 represents: - dioxothiomorpholino moiety B1; - piperazinyl moiety B2 wherein two carbon atoms of the piperazine ring can be optionally joined with methylene bridge -CH 2 - to form 2,5-diazabicyclic moiety, and R 5 is selected from the group consisting of -SO 2 CH 3; -C -C1-C3-alkyl, -C -C3-C5-cycloalkyl; phenyl substituted with -O-C1-C3 alkyl; and -CR 6 R 7 R 8, - dioxothiomorpholino moiety B1; - piperazinyl moiety B2 wherein two carbon atoms of the piperazine ring can be optionally joined with methylene bridge -CH 2 - to form 2,5-diazabicyclic moiety, and R 5 is selected from the group consisting of -SO 2 CH 3; -C -C1-C3-alkyl, -C -C3-C5-cycloalkyl; phenyl substituted with -O-C1-C3 alkyl; and -CR 6 R 7 R 8, wherein R 6, R 7 and R 8 independently represent hydrogen atom, CH 3, cyclopropyl or CONH 2, with the proviso that only one of R 6, R 7 and R 8 can represent cyclopropyl or CONH 2, or one of R 6, R 7 and R 8 represents hydrogen atom and remaining two of R 6, R 7 and R 8 are joined together to form -(CH 2) 2, -(CH 2) 3, -(CH 2) 4, or -(CH 2 -O-CH 2)- group; - azetidinyl moiety B3 wherein R 9 is selected from the group consisting of morpholino, 2,6-dimethylomorpholino, 1,1-dioxothiomorpholino, 4,4-difluoropiperidynyl and 3-methoxyazetidin-1-yl; or - piperidinyl moiety B4 wherein R 10 is selected from the group consisting of C1-C4 alkyl; C1-C4 alkyl substituted with OH; -COO(C1-C3 alkyl); -N(C1-C3 alkyl) 2; -NHCONH-C1-C3-alkyl; -NHCONH-C1-C3-phenyl; piperazinyl; and piperazinyl substituted at the position 4 with C1-C3 alkyl; - azetidinyl moiety B3 - piperidinyl moiety B4 R 3 is selected from the group consisting of H, halogen, and C1-C4 alkyl; R 4 is selected from the group consisting of C1-C4 alkyl, C3-C4-cycloalkyl, C1-C4 alkyl substituted with C1-C4 alkoxy, and CHF 2; X 1 and X 2 have the following meanings: (i) X 1 represents CH and X 2 represents CH or N; (ii) X 1 represents N and X 2 represents CH, or (iii) X 1 represents CH and X 2 represents C-O-CH 3; (i) X 1 represents CH and X 2 represents CH or N; (ii) X 1 represents N and X 2 represents CH, or (iii) X 1 represents CH and X 2 represents C-O-CH 3; X 3, X 4, X 5 and X 6 have the following meanings: (i) X 3 represents N, X 4 represents CH, X 5 represents CH, and X 6 represents CH; (ii) X 3 represents CH, X 4 represents N, X 5 represents CH, and X 6 represents CH; (iii) X 3 represents CH, X 4 represents CH, X 5 represents N, and X 6 represents CH; (iv) X 3 represents CH, X 4 represents CH, X 5 represents CH, and X 6 represents CH or CF; or (v) X 3 represents CH, X 4 represents CH, X 5 represents CF, and X 6 represents CH; (i) X 3 represents N, X 4 represents CH, X 5 represents CH, and X 6 represents CH; (ii) X 3 represents CH, X 4 represents N, X 5 represents CH, and X 6 represents CH; (iii) X 3 represents CH, X 4 represents CH, X 5 represents N, and X 6 represents CH; (iv) X 3 represents CH, X 4 represents CH, X 5 represents CH, and X 6 represents CH or CF; or (v) X 3 represents CH, X 4 represents CH, X 5 represents CF, and X 6 represents CH; X 7 represents CH or N; wavy line indicates the point of attachment; and pharmaceutically acceptable salts thereof.